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PERANAN ESTROGEN DALAM PENGHASILAN ANTIBODI 
OLEH SEL B YANG DISTIMULASI OLEH IL-27 
ABSTRAK 
 
Sistemik lupus eritematosus (SLE) adalah penyakit autoimun yang 
melibatkan organ-organ dan menyebabkan kerosakan tisu serta menghasilkan ciri-
ciri klinikal yang pelbagai. Tahap serum interleukin (IL)-27 telah dilaporkan 
meningkat dalam pesakit SLE berbanding penderma yang sihat. Tambahan pula, 
tahap serum IL-27 memainkan peranan dalam perkembangan sel B dan penghasilan 
auto-antibodi. Kebanyakan pesakit SLE adalah wanita yang dalam linkungan umur 
yang berpotensi untuk melahirkan anak. Oleh itu, hormon estrogen telah 
dicadangkan memainkan peranan penting dalam penyakit SLE. Oleh yang demikian, 
tujuan kajian ini adalah untuk membandingkan tahap serum IL-27 dalam pesakit 
SLE dan penderma yang sihat. Selain itu, kajian ini juga bertujuan untuk mengkaji 
potensi kesan estrogen khususnya terhadap penghasilan antibodi oleh sel B yang 
telah distimulasi oleh IL-27 dalam kondisi pesakit SLE dan penderma yang sihat. 
Teknik pengasingan serum telah dilakukan ke atas 39 orang pesakit SLE dan 39 
orang penderma yang sihat dengan menggunakan teknik pengemparan. Tahap serum 
daripada kumpulan pesakit SLE dan penderma yang sihat telah diukur dengan 
menggunakan teknik ELISA dan data dianalisa menggunakan GraphPad Prism, versi 
5.01. Perbandingan di antara kedua-dua kumpulan tersebut juga dianalisa 
menggunakan ujian Mann Whitney. Untuk mengkaji peranan hormon estrogen 
dalam penghasilan antibodi oleh sel B yang telah distimulasi oleh IL-27, 20 ml 
darah telah diambil daripada 3 individu pesakit SLE dan 3 individu penderma yang 
sihat. Sel B telah diasingkan daripada sel mononuklear darah daripada setiap 
 xvi 
kumpulan menggunakan teknik pengasingan magnetik. Sel B yang tulen seterusnya 
telah distimulasi dengan anti-IgM, CD40 ligand, rekombinan IL-27 dan kemudian 
dirawat dengan 1000 nM 17β-oestradiol (estrogen) dan dikultur selama 48 jam di 
dalam 37ºC inkubator karbon dioksida.  Supernatan daripada sel yang telah dikultur 
diambil dan ELISA IgG telah dilaksanakan untuk kedua-dua kumpulan. Tahap 
serum IL-27 dalam pesakit SLE lebih tinggi berbanding penderma yang sihat. 
Dalam penderma yang sihat dan pesakit SLE, keputusan menunjukkan penghasilan 
antibodi adalah rendah apabila sel B yang distimulasikan oleh IL-27 dirawat dengan 
estrogen berbanding dengan kondisi yang tidak dirawat dengan estrogen. 
Kesimpulannya, dalam kondisi normal dan SLE, kehadiran estrogen dengan sel B 
yang distimulasi oleh IL-27 mempunyai kesan terhadap penghasilan antibodi dan 















THE ROLE OF OESTROGEN IN ANTIBODY PRODUCTION BY 
IL-27 STIMULATED-B CELLS  
ABSTRACT 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease involving 
multiple organs and this disease can lead to tissue damage and diverse clinical 
manifestations. Serum level of interleukin (IL)-27 was reported to be elevated in 
SLE patients compared to healthy donors. In addition, serum level of IL-27 plays a 
role in B cell development and autoantibody production. Since most SLE patients 
are women of child-bearing age, oestrogen has been suggested to play an important 
role in SLE pathogenesis. Thus, this study aimed to compare the serum level of IL-
27 from SLE patients and healthy donors, and also to investigate the potential effects 
of oestrogen particularly on the antibody production by IL-27 stimulated-B cells in 
normal and SLE condition. Serum was isolated from 39 healthy donors and 39 SLE 
patients using centrifugation technique. Serum level of IL-27 from both healthy 
donors and patient groups were measured using ELISA. The data were analysed 
using GraphPad Prism, version 5.01. Comparison between SLE patients and healthy 
donors groups was done using Mann Whitney test. To investigate the role of 
oestrogen in antibody production by IL-27 stimulated-B cells, 20 ml of blood was 
collected from 3 healthy donors and 3 SLE patients.  B cells were isolated from 
peripheral blood mononuclear cells (PBMCs) of both groups using magnetic 
separation technique. The purity of B cells was checked using flow cytometry. 
Purified B cells were stimulated with anti-IgM, CD40 ligand, and recombinant IL-
27, then treated with 1000 nM of 17β-oestradiol (oestrogen) before cultured for 48 
hours in 37ºC in CO2 incubator. The supernatants of the cultured cells were 
 xviii 
collected to measure total IgG ELISA for both healthy donors and SLE patients. The 
serum level of IL-27 in SLE patients was higher compared to healthy donors. In 
healthy donors and SLE patients, total IgG concentration was lower when IL-27 
stimulated-B cells treated treated with 17β-oestradiol compared with untreated 
condition. In conclusion, in normal and SLE condition, oestrogen does have an 
effect on IL-27 stimulated-B cells through the antibody production and has a critical 
























1.1  The immune system 
Immune system is a critical defense system in human body. Immune system comprised 
of the entire organs, vessel systems, individual cells and proteins which is explicitly 
coordinated to react against infection (Abbas et al., 2015). The immune protection from 
threats is crucial without activating abnormal response to self-antigens that can lead to 
autoimmunity (Mangino et al., 2017). Human immune system varied between 
individuals but relatively stable over time for each person (Brodin and Davis, 2017).  
1.2  The organ of the immune system 
Several organs are involved in immune system which comprise of primary and 
secondary lymphoid organs. The examples of primary lymphoid organs are bone 
marrow and thymus. Bone marrow is a tissue located in the bone and produces most of 
the defence cells and also proliferate in there (Abbas et al., 2015). Immune cells 
produced in the bone marrow migrate to the bloodstream as well as organ and tissue, 
where they mature and become specialised cells. Meanwhile, the thymus (thymus gland) 
is located above the heart which is behind the breast bone, where T lymphocytes (T 
stands for thymus) differentiate and mature in the thymus and later move throughout the 
whole body to constantly do its defence role (Kurd and Robey, 2016; Abbas et al., 
2015).  
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Meanwhile, secondary lymphoid organs consist of the lymph nodes, spleen, 
tonsils and mucosal-associated lymphoid tissue (Randall et al., 2008; Drayton et al., 
2006). Lymph nodes are small kidney-shaped in size and located throughout the body 
(Moore Jr and Bertram, 2018; Nurken and Marzhan, 2016). They are structurally 
organised with separated regions (cortex, paracortex and medulla) which consists of 
different immune cells in each region (D’Rozario et al., 2018). Meanwhile, spleen is 
located beneath the diaphragm at the upper left abdomen, and structurally organised into 
red and white pulp. Red pulp region is rich in macrophage and erythrocyte for 
surveillance role from blood-borne pathogens, meanwhile, white pulp is enriched with 
supports for antigen-specific immune response (Golub et al., 2018; Steiniger et al., 
2011). In addition, tonsil is located at the wall of oral pharynx which its role is mainly to 
defend the body from ingested or inhaled pathogens (Hosokawa et al., 2017). The 
mucosal-associated lymphoid tissue provides protection at mucosal surfaces for 
example, in lungs, reproductive tract, and gastrointestinal tract (Drayton et al., 2006). 
The presence of mucous membrane in the nose and the urinary bladder or vagina is the 
first line of defence to prevent the bacteria and viruses from attaching and harming the 
body (Zhang et al., 2016b) 
1.3  The cells of the immune system 
First and second line of defence is crucial in the immune system. Various immune cells 
are designed to be part of the immune response upon exposure to extracellular or 
intracellular pathogens. The first line of defence or known as the innate immune 
response involves neutrophils, basophils, macrophages, dendritic cells (DCs), and 
monocytes (Simon et al., 2015). These cells will interact with cells in the adaptive 
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immune system which are T and B cells as well as natural killer (NK) cells. In immune 
system, majority of cells are derived from progenitor’s stem cell in the bone marrow. T 
and B cells that already mature will circulate in the bloodstream and some will assemble 
in specialised lymphoid tissue (Todd, 2010). During adaptive immune response, more 
cells are activated upon pathogens exposure. Importantly, this type of immunity has a 
vital function to distinguish foreign from self (Ketelhuth and Hansson, 2016).  
1.3.1  T cell development 
Cortex and medulla are the sites where T cell developed in the thymus. T cells 
progenitors migrated into thymus via blood vessels. The α and β loci of T cell receptor 
(TCR) rearrangement occur at the outer region of thymic cortex in order to respond to a 
wide range of foreign antigens (Kurd and Robey, 2016). During the development, T 
cells go through multiple differentiation steps based on the expression of CD4 and CD8 
cell-surface marker. T cells with lack of receptor expression which is the early T cells 
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). DN2 is the pivotal stage where the 
thymocytes undergo normal T lineage specification (Li et al., 2010a).  
The signalling facilitated by the interaction of TCR with self-peptide major 
histocompatibility complex (MHC) ligands affects the fate of DP thymocytes. 




 T cells meanwhile, those with TCR expression that bind to self-peptide MHC 
II complexes develop into CD4
+
 T cells (Germain, 2002). Positive selection is essential 
for thymocyte survival either to become CD4 or CD8 T cells. Besides, thymocytes that 
recognise self-antigen mediate negative selection (Klein et al., 2014). Naïve T cells 
recirculate in the bloodstream and secondary lymphoid organs (Palmer et al., 2015). 
Competent thymocytes then move out from thymus as functional mature T cells (Kurd 
and Robey, 2016).  
1.3.2  B cell development  
B cells derived from hematopoietic stem cells in the bone marrow with organised 
selection and maturation process. The migration of hematopoietic cells occur from inner 
bone surface to central area of bone marrow cavity (Nagasawa, 2006). Developed B 
cells migrate into the blood before reaching the peripheral lymphoid organs (Pieper et 
al., 2013). Development of B cells is an ordered process resulting in sequential 
expression and assembly of B cell receptor (BCR). BCR composed of heavy and light 
chain of ligand-reorganizing immunoglobulin (Ig) in non-covalent association with Igα 
and Igβ transmembrane protein (Pieper et al., 2013; Monroe et al., 2003).  
B cell development is organised throughout the process functional rearrangement 
of Ig gene segment. A random process of gene assortment to recombine heavy and light 
chain can result in more than 4 million different combinations (Dunn-Walters, 2015). 
Heavy chain (VH, DH, and JH) with light chain (VL-JL) gene segment rearrange to 
produce B cell lineage expressing antibodies that recognize more than 50 trillion 
different antigens (Pieper et al., 2013). The first stage in the rearrangement process, pro-
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B cells rearrange D and J segments of heavy chain. Then, second rearrangement process 
occurs by joining the upstream of V region to rearrange DJ segment. Heavy chain gene 
segment with functional rearrangement leads to the next phase entry which is the pre-B 
cell stage (Pieper et al., 2013). Only functional heavy chain effectively binds to 
surrogate light chain and kappa or lambda light chain will survive and further develop 
(Dunn-Walters, 2015). The combination of μ chain forms IgM molecule expressed on 
the surface of the cell to become immature B cells and ready to migrate from the bone 
marrow. The immature B cells migrate into spleen where they finalise early 
developmental process then, differentiate into naïve, marginal zone (MZ)  and follicular 
B cells (Pieper et al., 2013). Antibody affinity maturation takes place during B cells 
differentiation in germinal centre (GC) (Zhang et al., 2018b; Victora and Nussenzweig, 
2012). T follicular regulatory (Tfr) cells regulate the response in the GC upon receiving 
survival signals from Tfh cells. Response in the GC occurs before further process of 
proliferation to produce high affinity antibody secreting plasma cells or memory B cells 
(Figure 1.1) (Stebegg et al., 2018). Besides, cytokine such as IL-27 was reported to 











Figure 1.1: Germinal centre (GC). This specialised microenviroment is divided into two 
distinct compartments which are dark zone and light zone. GC is formed within B cell 
follicles of secondary lymphoid tissues upon infection and immunisation. Adapted from 







During development, B cells are screened at multiple check points in order to avoid 
auto-reactivity. In addition, mature B cells consist of three major subsets; B1 cells, 
follicular B cells, and MZ B cells (Nutt et al., 2015). Mature B cells recirculate between 
secondary lymphoid organs in order to identify foreign antigen (Nutt et al., 2015). 
1.4  The immune response 
Human has a sophisticated immune response against evolutionised pathogens that can 
cause infection and any dysregulated auto-reactivity leading to autoimmune disease. 
Immune response comprised of two systems which are innate and adaptive immune 
responses. The innate immune response is immediate and nonspecific meanwhile, 
adaptive immune response is specific and also known as acquired immunity. Although 
innate and adaptive immune responses are usually described as contradictory with 
different mechanism of action, however, they need to interact with each other with the 
DC presented the antigenic peptide into MHC proteins to T cell until the antibody and 
memory are produced (Yatim and Lakkis, 2015). This interaction between innate and 
adaptive immune system is crucial in order to possess effective immune response 
(Chaplin, 2010). Infections are recognized by innate immune system to give the 
immediate defence responses with recognition system linked to adaptive immunity for 
generation of long lasting defence (Iwasaki and Medzhitov, 2015). Innate and adaptive 
immune response against pathogens activates complement system which improve the 
capability of antibody and phagocytic cells to abolish microbes and damaged cells. 
Complement system activation promotes inflammation, lysis and opsonisation of the 
antigen (Dunkelberger and Song, 2010). 
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1.4.1 Innate immune response 
Innate immune response is a rapid and non-specific response towards pathogens. Innate 
immunity facilitated by pattern-recognition receptor (PRR) that detect pathogen-
associated molecular pattern (PAMP) such as cell wall of certain bacteria, virus, fungi 
and unrecognised nucleic acid. PRR is expressed on the plasma membrane of 
macrophages, DCs and other types of host cells. Induction of inflammatory response and 
innate host defence is the result of detection of PAMP by PRR (Iwasaki and Medzhitov, 
2015).  
Epithelial cells with chemical and biological agents such as lysozyme and 
phospholipase ensure the effectiveness of first line of defence. Macrophages and 
neutrophils are examples of professional phagocytes where they eliminate the pathogens 
via phagocytosis. Other than destroying pathogens, phagocytes also act as antigen 
presenting cells (APCs) that can alert the adaptive immunity to respond to the invaders. 
DCs and monocytes are the examples of professional APC. They act upon the pathogens 
by cellular uptake and then taken up the proteins of the pathogens. After that, the APC 
will present the protein from the pathogens on its surface by major histocompatibility 
complex Class II (MHCII) to alert the adaptive immunity. Other examples of phagocytes 
are eosinophils, basophils and mast cells. Furthermore, the non-self particles captured by 
non-professional phagocytes for example, the epithelial cells, are still needed to be 
eliminated by macrophages that redirect phagocytosis process. Particles that engulfed by 
non-professional phagocytes are modified by macrophages before undergo redirect 
phagocytosis and induce their inflammatory response (Han et al., 2016).  
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In addition, NK cells, the cytotoxic cells are also one of the innate immunity 
components. NK cells kill the infected cells by inducing cell death. NK receptor 
distinguish MHC Class I (MHC-1) molecules to recognise between infected and healthy 
cells and attack any cells with infection, malignancy or any form of stress from cells 
(Parham and Guethlein, 2018). However, if the infection persists, adaptive immunity 
will take action to fight the infection. 
1.4.2 Adaptive immune response 
Adaptive immune response takes place when innate immune response unable to 
eliminate pathogens. Adaptive immunity is specific towards invading pathogens and 
long lasting mainly due to the generation of memory. Thus, the immune response will be 
rapidly activated when encounter the same pathogens later in life. Adaptive immunity 
permits recognition of millions of different molecular structures that mediated by surface 
receptors. The specific surface receptors lead to specific recognition by TCR and BCR 
structurally and functionally (Ketelhuth and Hansson, 2016).  
Professional APC such as DC engulfs invaded pathogens and present part of the 
pathogens to the surface via MHC Class II. The activated DCs migrate to local lymph 
nodes and then present the part of pathogen protein to T and B cells (Appenheimer and 
Evans, 2018). T and B cells that are specific will recognise the pathogen’s protein and 
bind to the antigen presented on the DCs surface. This specificity of T and B cells occurs 
by random recombination of gene segment during development stage (Kurd and Robey, 
2016; Dunn-Walters, 2015).  Upon binding with the antigens, T and B cells become 
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activated and differentiate into effector cell type which activates phagocytic cells such as 
macrophage to destroy the pathogens. 
1.4.3  T cell activation 
Activation of naïve T cells will occur upon interaction with APC for examples, 
macrophages, DCs, and B cells. Specifically, T cells become activated by a combination 
of antigen-specific signals from TCR and antigen-independent signalling from co-
signalling receptors. Co-signalling receptor consists of costimulatory and co-inhibitory 
receptors expressed on T cell surface (Hui et al., 2017). Two simultaneous signals are 
needed to activate T cell (Pollard, 2007). The first one is by the antigen presentation in 
complex with MHC by APC and being recognised by antigen-specific receptor on the 
surface of T cell. The second signal is by costimulatory signals which is crucial for T 
cell to become activated, for example, CD28 ligand on T cells with CD80/CD86 ligand 
on the APC that interact for initial activation of T cell (Pollard, 2007). In addition, 
cytokines release by APCs are also essential for improvement of T cell activation and 
influence T cell differentiation to become effector cell types (Pennock et al., 2013). The 
activated T cell increase the APC activity via interaction of CD40-CD40 ligand to 
release cytokines such as interferon gamma (IFN-γ) and GM-CSF (Hernandez et al., 
2007).  However, before the activation occurs, specific effector functions are required 
for a condusive metabolic condition, which is glucose metabolism to regulate the T cell 
activation (Palmer et al., 2015). This is to ensure T cells have ATP-generating processes 
and high metabolic flux to support their functional needs especially in combating 
infection (MacIver et al., 2013).  
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1.4.4 B cell activation 
B cell becomes activated when BCR recognises and binds to its complementary antigen. 
B cells activation occurs at secondary lymphoid organs for example at spleen and lymph 
nodes. B cells can be activated either with T-independent (TI) response which activation 
is without T cell interaction or with T-dependent (TD) response which requires CD4
+ 
T 
cells interaction. B1 cells, MZ B cells, and follicular B cells are able to respond towards 
antigens by TI response (Nutt et al., 2015). 
The TD response is a two-step process in which both steps provide instant and 
persistent protection. The first is called extra-follicular response that involve B cell 
receiving signal from antigen receptor-dependent that lead to B lymphoblast 
development (involve with recombination of Ig class-switch) and short-lived 
plasmablast that produce antibody (De et al., 2018). This process exhibits little somatic 
hypermutation, thus, the antibody produced for the antigen have a tendency to be 
moderate and fixed. The second step of TD response occurs by the effect of specialised 
T follicular helper cell. Some activated B cell re-enter B cell follicle and some also 
proliferates vigorously to form a GC (Nutt et al., 2015). In addition, the activated T cell 
also produces cytokine to promote B cells differentiation and specify the subtype of 
antibody secreted (De et al., 2018).  
Immediately after B cell activation either by TI or TD, B cell undergoes 
differentiation to become antibody-secreting cells known as plasma cells. These plasma 
cells produce high titres of antibody specific to the antigen, which are released into 
circulation to neutralise the invading antigen (De et al., 2018). However, plasma cell 
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does not respond to secondary infection as they have low BCR surface expression. The 
antibody remains in the circulation for several months. Meanwhile, B cell activation via 
TD produces memory B cells that remain in the tissue and circulation for a longer 
period. These memory B cells multiply extensively but do not secrete antibody. Contrary 
to plasma cell, memory cell maintain BCR expression on its surface and rapidly produce 
the antibody after encounter with the same antigen later in life (Nutt et al., 2015). Figure 
1.2 shows the summary of developmental stages of B cells and their differentiation until 

















Figure 1.2: Developmental stages of B cells. The developmental stage of B cells from 
bone marrow together with differentiation and maturation stage in secondary lymphoid 









1.5 The cytokine 
Cytokine is a cell-signalling protein molecule that activates and regulates immune 
responses (Schirmer et al., 2018). Other names of cytokine include chemokine, 
interleukin (IL) (Zhang and An, 2007), interferon (IFN), granulocyte colony-stimulating 
factor (G-CSF), tumour-necrosis factor (TNF), and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Holdsworth and Gan, 2015). These polypeptide 
glycoproteins with low molecular weight are synthesised by different immune cells such 
as T cells, B cells, stromal cells neutrophils and macrophage (Ferreira et al., 2018; Jandl 
and King, 2016). Cytokine is essential in immune response by inducing local 
inflammation protection and response of systemic acute phase both in innate and 
adaptive immunity (Holdsworth and Gan, 2015).  
Cytokine can be divided into functional classes such as primary lymphocytes 
growth factors, pro-inflammatory or anti-inflammatory factors and functioning mainly in 
immune response to antigen (Dinarello, 2007). However, some cytokines exert multiple 
actions (called pleiotropic) that leads to the ability to activate multiple signalling 
pathways that contribute to different functions (Ozaki and Leonard, 2002).  
1.6  Tolerance and autoimmunity 
1.6.1  Tolerogenesis 
The immune system is able to differentiate between self and non-self-antigen. The 
system has several checkpoints to prevent cells with self-responsive antigen receptors 
that can lead to autoimmunity. The first selective checkpoint occurs in primary lymphoid 
organs during lymphocytes development process which is termed as central tolerance 
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(Anderson et al., 2017). Second selective checkpoint is implemented once the cells enter 
the circulation and termed as peripheral tolerance (Anderson et al., 2017).  
1.6.2  Central T cell tolerance 
In the thymus, clonal deletion is one of the important mechanisms of T cell tolerance. 
Cortex region is where thymocytes undergo positive selection, while the deletion occurs 
during the transition phase from double negative (DN) to double positive (DP) that 
occurs in the thymic cortex (Xing and Hogquist, 2012). Tissue-specific antigens are 
usually exclusively expressed in the thymic medulla. In addition, the development of T 
cell that includes clonal deletion is depending on the connections with other cells (e.g. 
macrophages, epithelial cells, and DC) in the thymic microenviroment. During thymic 
tolerance, medullary thymic epithelial cells (mTECs) play a crucial role and a nuclear 
regulatory protein called autoimmune regulator (AIRE) gene will be expressed (Yamano 
et al., 2015; Xing and Hogquist, 2012). 
During this stage of T cell tolerance, AIRE, which is highly expressed in thymic 
medulla specifically in mTECs, plays its role as the master regulator and important 
during this stage of tolerance (Proekt et al., 2017; Abramson and Husebye, 2016; Chan 
and Anderson, 2015; Yamano et al., 2015). This gene helps to remove the thymocytes 
with self-reactivity from T cell repertoire via negative selection (Cheng and Anderson, 
2018).  
Like mTECs, medullary and cortical DCs are also have a vital role in central T 
cell tolerance by promoting the apoptosis to self-tolerance thymocytes (Yamano et al., 
2015; Xing and Hogquist, 2012). Based on ‘affinity model’ of selection, thymocytes 
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with low affinity of self-peptide-MHC will induce positive selection, whereas those with 
high affinity experience negative selection (Starr et al., 2003).  
1.6.3  Peripheral T cell tolerance 
Although the mechanism of central tolerance is efficient, not all self-reactive T cells can 
be removed and some will escape into periphery. Therefore, peripheral tolerance exists 
to control lymphocytes tolerance outside of the thymus (Xing and Hogquist, 2012). In 
peripheral T cell tolerance, some of the escaped precursors that display TCR with high 
affinity towards self are being eliminated either by negative selection or restrained by 
regulatory T (Treg) cells. Treg cells differentiate and functioned with the control of X-
chromosome-encoded Forkhead box P3 (Foxp3) transcription factor which expressed on 
the self-reactive T cells that escape negative selection (Feng et al., 2015).  
  Besides, anergy which is a condition of unresponsiveness, and self-reactive T 
cells deletion can take place in the periphery (Xing and Hogquist, 2012). T cells become 
activated with the presence of TCR signalling and costimulatory signal pathway or 
secondary signal (Xing and Hogquist, 2012). Negative second signals provided by 
costimulatory pathways to prevent T cell response, facilitate tolerance of T cell and 
inhibit autoimmunity (Xing and Hogquist, 2012). Ligation of TCR and programmed 
death 1 (PD-1) receptor control self-reactivity and limit the first activation phase and 
self-reactive T cell expansion (Xing and Hogquist, 2012). 
In addition, peripheral DC is also an important regulator of inducing and 
maintaining tolerance. Tolerogenic DCs can express PD-1 ligands to regulate the 
decision between T cell tolerance and activation (Xing and Hogquist, 2012). 
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1.6.4 Central B cell tolerance 
Effective selection system of immune system is needed to prevent the migration of 
mature autoreactive B cells into circulating B cells pool (Pieper et al., 2013). During 
central B cell tolerance, the immature B cell that recognise high affinity self-antigen in 
the bone marrow will be deleted or activate the receptor editing to alter their specificity. 
Whether to be deleted or undergo receptor editing is dependent to the BCR signalling. 
High affinity autoantigen that bind with strong BCR signal will continue to deletion or 
receptor editing. Meanwhile, the binding with intermediate affinity will allow B cells to 
endure and survive before entering the periphery (Tobón et al., 2013).  
Major mechanism of central B cell tolerance is by receptor editing. Unlike T 
cells, B cells have other chance to escape negative regulation which the receptors 
undergo editing their specificities together with additional antibody gene 
rearrangements. In the bone marrow, immature B cells that encounter self-antigens will 
return to pre-B stage. Then, they will continue to rearrangement process to generate new 
B cells that no longer self-reactive. Then, this new novel rearrangement of immature B 
cells will move into periphery and become mature circulating B cells (Tobón et al., 
2013).  
Immature B cells at about 30% - 35% experience receptor editing. Meanwhile, the 
remaining of autoreactive immature B cells will undergo other selection processes, 
which are clonal deletion, ignorance or anergy (Pelanda and Torres, 2012). These 
mechanisms lead to the autoreactive clones to be deleted and prevent self-reactivity. 
Besides, apoptosis will occur when immature B cell reacts with high avidity self-
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antigen. In contrast, low avidity B cells interact that with self-antigen will induce  
anergy or unresponsiveness to stimulation and permitted the migration to peripheral 
(Gururajan et al., 2014). Although clonal deletion is not the primary mode of negative 
selection, it acts as default mechanism when receptor editing fails (Pelanda and Torres, 
2012). Increased reactivity level known to be associated with the defective negative 
selection by reduction of receptor editing or impaired apoptosis (Nemazee, 2017). 
1.6.5  Peripheral B cell tolerance 
Survived immature B cells from central tolerance leave the bone marrow to become 
transitional B cells in the periphery. B cells go through negative and positive selection as 
they mature in the periphery (Stadanlick and Cancro, 2008). These B cells undergo 
tolerance based on their specificity of BCR and the strength of signal. The selection 
occurs based on the interaction between BCR-mediated signals and B cell survival factor 
called B lymphocyte stimulator/ activator (BAFF) or also known as BLyS signalling 
bind to BAFF receptor (BAFF-R) (Gururajan et al., 2014; Pieper et al., 2013; Scholz et 
al., 2013). Deficiency of BAFF results in the reduction of the number of peripheral B 
cell and reduced the ability to support the humoral immune response. Meanwhile, 
overexpression of BAFF is associated with human autoimmunity and lead to defect in 
tolerance of transitional B cell during peripheral tolerance. Thus, B cells that are usually 
be deleted during negative selection would survive due to overexpression of  BAFF 
signalling and enter periphery (Gururajan et al., 2014).  
If autoantigens being recognised by mature B cells in peripheral tissues in the 
absence of specific helper T cell response, the function of the cell will be inactivated by 
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anergy or die by apoptosis (Tobón et al., 2013). Peripheral B cells survive by excluding 
B cells that consist of autoreactive BCR transgene from splenic follicles will die rapidly 
when competing with normal B cells (Stadanlick and Cancro, 2008). Some self-reactive 
B cells in the periphery are not deleted but they would not differentiate to plasma cells 
even with the interaction with self-antigens due to clonal ignorance (Tsubata, 2017).  
1.7  Mechanisms to tolerance disruption 
Human body is responsible to maintain all of the above mechanisms for tolerance 
towards self-antigens. The breakdown or defective of the mechanisms can cause 
autoimmunity. T and B cells bound to high avidity self-antigen will undergo tolerance 
process during central tolerance. However, if the central tolerance fails to avoid 
lymphocytes with self-antigens, the elimination process will proceed in the periphery to 
avoid autoimmunity, termed as peripheral tolerance. There are many factors that 
tolerance can be disrupted, leading to autoimmunity. Some of the factors causing 
autoimmunity are detailed below. 
1.7.1 Increase exposure to antigen 
Self-antigen exposure or expression level is too low to induce tolerance may occur for 
several reasons. One of it is defective expression of antigens in the thymus which 
prevent negative selection of self-reactive T cells. As described above, AIRE gene helps 
to remove the thymocytes with self-reactivity from T cell repertoire via negative 
selection (Cheng and Anderson, 2018). The increase exposure to antigen may lead to 
tolerance disruption and cause autoimmunity. Thus, AIRE can prevent autoimmunity by 
tissue-specific antigen (TSA) upregulation of expression in mTECs. These thymic TSAs 
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is recognised by self-reactive T cells that lead to clonal deletion and/or lineage of 
regulatory T cell diversion (Anderson and Su, 2016). Besides, AIRE gene is also 
identified to cause multi-organ system autoimmunity in human and plays a role in 
thymic tolerance.  
1.7.2 Ineffective clearance of apoptosis cells 
Autoimmunity is associated with ineffective or failed clearance of apoptotic cells. The 
process of programmed cell death or apoptosis that includes multiple steps which 
involve caspase activation after the cell is impaired by physiological and pathological 
stimuli (Jung and Suh, 2015). Regulation of apoptotic cell death naturally preserves the 
integrity of membrane and avoid the potential inflammatory and intracellular contents to 
be released (Nagata, 2018; Elliott and Ravichandran, 2010). Damaged and dead cells as 
well as debris are rapid and efficiently cleared by professional phagocytes in an 
immunologically silent manner (Mahajan et al., 2016). However, if slow clearance of 
apoptotic cells occurs, it will lose the membrane integrity and proceed to secondary 
necrosis. DNA and intracellular antigens release from dying cells would provoke an 
inflammatory response, thus leading to autoimmune disorder (Elliott and Ravichandran, 
2010). Apoptotic cells with defective clearance may contribute to the accumulation of 
apoptotic debris and the autoantigens from secondary necrotic cells may be released 
(Shao and Cohen, 2011). In addition, the autoantigens is produced from inefficiency of 
the DNA-containing neutrophil extracellular traps (NETs) degradation that lead to 
autoimmunity (Mahajan et al., 2016). 
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1.7.3 Molecular mimicry 
One of the multifactorial causes of autoimmunity in human is due to cross-reactive 
epitopes or known as molecular mimicry. Molecular mimicry is the sharing of epitopes 
among self and non-self antigen where the foreign antigen shares similar structural 
sequence with self-antigens (Rose, 2015; Cusick et al., 2012) favour an activation of 
autoreactive T or B cells in susceptible individual (Rojas et al., 2018a). Self-reactive T 
and B cells that undergo incomplete negative selection will lead to cross-reacting 
epitopes commonly occur between invaded microorganism and the host (Rose, 2017). 
Furthermore, the cross-reactive epitopes may occur due to the inflammation that is 
caused by foreign antigen. When T and B cells presented these foreign antigens together 




T cells. Clearance of invaded pathogens will 
occur and pro-inflammatory cytokine will be secreted. However, this pro-inflammatory 
response can occur to specific host tissues due to the sequence and similar structure 
between foreign and self-antigens known as molecular mimicry, leading to 
autoimmunity (Cusick et al., 2012).  
1.7.4 Marginal zone B cells and autoimmunity 
Marginal zone (MZ) B cells carrying antigen into the follicles. They are a potent 
activator for T cell with rapid response than follicular B cells (Zhou et al., 2011; 
Cinamon et al., 2008; Attanavanich and Kearney, 2004). MZ B cells can also 
differentiate rapidly into plasma cells (Zhou et al., 2011). In autoimmunity, MZ B cells 
are enhanced for autoreactive specificities via self-reactive germline-encoded BCR 
expression (Zhou et al., 2011; Bendelac et al., 2001). MZ B cells carry BCRs which are 
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specific for self-antigens and cannot be deleted by mechanism of self-tolerance, thus 
affecting in maintenance of homeostasis (Palm et al., 2015).  
1.7.5 Germinal centre dysfunction that leads to autoimmunity 
Germinal centre (GC) that forms in secondary lymphoid organs is a dynamic 
microenvironment. GC functioned to produce somatically mutated high-affinity 
antibodies that is required for an effective humoral immune response (Domeier et al., 
2017; Gatto and Brink, 2010). Exaggerated chronic GC reactions may occur due to 
dysregulation of GC mechanisms in development and maintenance phase (Gatto and 
Brink, 2010). In addition, the production of autoantibodies also associated with the 
spontaneous GC formation (Domeier et al., 2017; Gatto and Brink, 2010). In fact, 
defective of molecules that aid in recognition, uptake and the digestion of apoptotic cells 
can make human susceptible to autoimmune disease (Gatto and Brink, 2010; Vinuesa et 
al., 2009).  
1.8 Autoimmune disease 
Autoimmune disease results from self-recognition by the immune system. It is a chronic, 
relapsing, and can be lethal, commonly characterized by defective of immune system 
lead to defective tolerance and over-expression of autoantibodies (Zhang and Lu, 2018). 
Diseases are termed as autoimmune when immune cells or antibodies recognize self-
antigens; the autoreactive antibodies resulting tissue injury and affects the organ; and the 
autoantibodies transfers to another human (e.g. maternal autoantibodies transfers to 
embryo caused neonatal lupus) (Moutsopoulos et al., 2018). Autoimmune disease can 
affect one organ which is known as organ-specific autoimmune disease and can also 
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affect many organs simultaneously and are known as systemic autoimmune disease 
(Moutsopoulos et al., 2018). Autoimmune disease involves both innate and adaptive 
immune responses (Theofilopoulos et al., 2017). Autoimmunity affects approximately 
eight percent of population globally and the incidence is increasing due to multifactorial 
reasons (Zharkova et al., 2017). The examples of autoimmune diseases are systemic 
lupus erythematosus (SLE), multiple sclerosis, rheumatoid arthritis (RA), Lyme disease, 
Sjogren’s syndrome, psoriasis, Graves’ disease, Crohn’s disease, and insulin-dependent 
Type 1 diabetes (Mahler, 2019; Pham and Mathis, 2019).  
1.8.1 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that leads to 
autoantibody production and multi-organ damage which mainly afflicts women in 
reproductive years (Katsuyama et al., 2018; Rider et al., 2018; Zhang et al., 2018a). 20 
to 150 cases per 100,000 population was stated as the SLE prevalence (Cai et al., 
2017a). The highest estimation of prevalence and incidence of SLE were in North 
America with 241/100,000 and 23.2/100,000 person-years respectively (Stojan and Petri, 
2018; Rees et al., 2017). The lowest prevalence was in Northern Australia with 0 case in 
a sample of 847 people (Stojan and Petri, 2018; Rees et al., 2017). In Malaysia which is 
a multi-racial country, SLE prevalence was higher in Chinese population, followed by 
Malays and generally low in Indians (Shaharir et al., 2016; Jasmin et al., 2013). 
However, the studies of SLE prevalence were not the latest and the trend would have 
changed in Malaysia and worldwide. 
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SLE is characterised by the breakdown of tolerance to self (Blanco et al., 2016) 
and involves systemic organ, due to systemic inflammatory response that leads to 
autoantibodies production causing multiple organs damage (Akizuki et al., 2019; 
Shaharir et al., 2019). It commonly affects skin, joints, kidney, musculoskeletal, 
hematopoietic system, and central nervous system (CNS) (Akizuki et al., 2019; Torell et 
al., 2019; Goulielmos et al., 2018; Katsuyama et al., 2018; Phuti et al., 2018). Severe 
organ damage such as renal failure and the involvement of CNS sometimes can be fatal 
(Akizuki et al., 2019). Many SLE patients experience “flares” of inflammation in one or 
more organ system, scattered times with inactive periods (Phuti et al., 2018). The precise 
mechanism of SLE remains unclear, however, the loss of immune tolerance is one of the 
main characteristics of SLE (Shao et al., 2019).  Even SLE is more frequent in women 
than men, it was reported that men have a more severe disease than women (Shaharir et 
al., 2019). In SLE, the severity or the disease activity index was evaluated using SLE 
disease activity index (SLEDAI) score with SLEDAI ≥ 4 is considered as active patient, 
while SLEDAI < 4 is considered as inactive patient (von Spee-Mayer et al., 2016; Lee et 
al., 2014). 
1.8.2  Pathogenesis of SLE and cytokines involved 
Various immunological abnormalities related to SLE have been identified in human and 
animal models. For instance, loss of B cell tolerance (Yang et al., 2015), T and B cell 
signalling with abnormal interactions, the hyperactivity of T and B cells (Jackson et al., 
2015; Moulton and Tsokos, 2015; Sanz, 2014; Tenbrock et al., 2007), production of 
pathogenic autoantibodies due to polyclonal B cell activation (Zhang et al., 2009), and 
the defective clearance of autoantigens and immune complexes (Malik et al., 2016). 
